Table 1.

Baseline characteristics and responses to treatment with rituximab for all subjects grouped according to baseline anti-PLA2R positivity and clearance versus persistence of anti-PLA2R at 12 months after treatment

AgeGenderDisease Duration (Months)Serum Creatinine (mg/dl)Creatinine Clearance (ml/min per 1.73 m2)Baseline Anti-PLA2R12-Month Anti-PLA2RBaseline Proteinuria (g/d)Outcome (12 Months)Outcome (24 Months)
Group 1: anti-PLA2R positive; clearance by 12 months
    140M61.011331,328011.8NRNR
    260F81.44628,56008.49PRCR
    353M61.37525,40108.48CRCR
    444M1441.68025,360495e11.87NRfPR
    552M61.57425,067014.69NRfPR
    638M400.815624,882610e8.32PRPR
    733M51.110923,985010.79CRCR
    846M81.38123,761280e10.09PRPR
    959M121.18722,46209.88PRRL
    1030M112.17322,251012.12NRfPR
    1151M242.33621,325016.27NRPR
    1247M121.84920,602014.23NRfPR
    1350M122.04619,487015.46PRPR
    1446M602.16119,062015.77PRCR
    1529M41.44918,585013.69NRfPR
    1657F40.83013,506660e8.59PRCR
    1764F351.089939507.02PRPR
Summary47 ± 1014:3111.5 ± 0.574 ± 3222,462a0b11.8
Group 2: anti-PLA2R positive; persistence at 12 monthsc
    1842M51.011931,994471026.46NRfPR
    1960M132.64031,42521,19020.08NRESRD
    2038M101.86831,08216,89023.44NRΔIST
    2149M371.47929,38163618.05NRΔIST
    2242M171.38329,28320,5959.88NRPR
    2363M61.56327,04157259.09NRΔIST
    24c80M42.03431,091NAc9.95ΔISTΔIST
    25c45M101.011421,903NAc8.85PRPR
Summary49 ± 106:011.51.6 ± 0.675 ± 2630,231a11,625b14.98
Group 3: anti-PLA2R negative
    2654M962.3049220d5.73PRPR
    2752M61.201450d7.76PRPR
    2837F100.9010208.4PRCR
    2953M131.8058023.54DiedDied
    3053M71.8059016.59NRESRD
    3144F80.7011606.1PRCR
    3243M1081.9059012.76NRNRf
    3329M51.00126011.33PRCR
    3462M71.4067019.16PRCR
    3542M121.109007.81PRPR
Summary47 ± 108:291.4 ± 0.587 ± 3409.86
  • Baseline and 12-month anti-PLA2R levels are presented in arbitrary densitometric units. Summary data are presented as means ± standard deviation or medians when appropriate. M, male; F, female; RL, relapse; ΔIST, change in immunosuppressive therapy; NA, not available.

  • Baseline and 12 month anti-PLA2R levels were significantly lower in group 1 than in group 2 (aP = 0.001; bP < 0.001). There were no other statistically significant differences between groups 1 and 2.

  • cTwelve-month serum samples were not available for subjects 24 and 25. They are included in group 2 for the purposes of this table, but they are not included in the statistical analyses or the summary data because we were unable to determine if there was a response in anti-PLA2R or not.

  • dThese two patients had faint visible bands that fell below the detection threshold of 1000 densitometric units when assayed at 1:25.

  • eThese bands were undetectable at a 10-second exposure but were visible at longer exposures; the anti-PLA2R level was extrapolated by calculating percentage of baseline value at the 10-second and longer exposure.

  • f“Limited” response (>50% decrease from baseline proteinuria but still >3.5 g/d).